GLP-1 Lasting Outcomes
US$ 29.61
mb glp 1 GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 GLP-1 and the New Consumer
Description
Nat Killer T Cell Divers Immunotherapy Cancers 2023;15
The STEP-HFpEF DM trial investigated whether the changes in glucose levels in HFpEF patients with obesity moderates the treatment benefits of GLP-1 RAs
The most commonly reported adverse events were nausea, diarrhea, and vomiting
The MHRA has issued a Drug Safety Update recommending B12 monitoring in patients on long-term metformin treatment
